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Effects of deep inspiration breath 
hold on prone photon or proton 
irradiation of breast and regional 
lymph nodes
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Wilfried De Neve1, Pieter Deseyne3, Leen Paelinck3, Tom Vercauteren3, Michael J. Parkes5, 
Tony Lomax2, Annick Van Greveling3, Alessandra Bolsi2, Damien C. Weber2,6,7, 
Liv Veldeman1,3 & Werner De Gersem1,3 
We report on a comparative dosimetrical study between deep inspiration breath hold (DIBH) and 
shallow breathing (SB) in prone crawl position for photon and proton radiotherapy of whole breast 
(WB) and locoregional lymph node regions, including the internal mammary chain (LN_MI). We 
investigate the dosimetrical effects of DIBH in prone crawl position on organs-at-risk for both photon 
and proton plans. For each modality, we further estimate the effects of lung and heart doses on the 
mortality risks of different risk profiles of patients. Thirty-one patients with invasive carcinoma of the 
left breast and pathologically confirmed positive lymph node status were included in this study. DIBH 
significantly decreased dose to heart for photon and proton radiotherapy. DIBH also decreased lung 
doses for photons, while increased lung doses were observed using protons because the retracting 
heart is displaced by low-density lung tissue. For other organs-at-risk, DIBH resulted in significant 
dose reductions using photons while minor differences in dose deposition between DIBH and SB were 
observed using protons. In patients with high risks for cardiac and lung cancer mortality, average 
thirty-year mortality rates from radiotherapy-related cardiac injury and lung cancer were estimated at 
3.12% (photon DIBH), 4.03% (photon SB), 1.80% (proton DIBH) and 1.66% (proton SB). The radiation-
related mortality risk could not outweigh the ~ 8% disease-specific survival benefit of WB + LN_MI 
radiotherapy in any of the assessed treatments.
Radiation therapy (RT) after breast-conserving surgery in locally advanced stage breast cancer improves locore-
gional control and  survival1. However, the benefit occurs at the expense of acute and late toxicity to the treated 
region, including but not limited to cardiac events, lung cancers and cancers in the contralateral  breast2–6. Car-
diac injury and cancer induction lead to excess mortality and are dose  dependent7. RT in prone position allows 
for dose reductions to lung and heart, hence lowering the risks of radiation-induced cardiac toxicity and lung 
 cancer8–11. Furthermore, prone positioning may be advantageous not only in whole breast (WB) irradiation, 
but also when combined with lymph node (LN) irradiation including the internal mammary (MI)  chain12,13. 
However, patient support devices for prone radiotherapy share several drawbacks for locoregional radiotherapy, 
such as patient discomfort and low set-up precision in the lateral  direction14. To address these problems, we have 
previously studied a novel ‘front crawl’ prone position for patients requiring locoregional treatment at Ghent 
 University12–14. Accordingly, we have also developed a prone support device (Prone Crawl Breast Couch) to facili-
tate patient positioning, CT-simulation and treatment. Using the Prone Crawl Breast Couch for the locoregional 
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treatment, without or with inclusion of the MI chain, we showed that dose reductions to lung, heart and other 
OARs could be obtained beyond what is achievable using advanced supine photon irradiation  techniques12,13.
The dose to the heart can be further reduced by using deep inspiration breath hold (DIBH) in prone or supine 
position, rather than with shallow breathing (SB)10. Imaging studies in prone position confirm that DIBH retracts 
the MI chain away from the  heart15. In a direct comparison of 4 techniques (prone or supine, SB or DIBH), prone 
DIBH achieved the lowest heart and lung doses for left-sided whole breast (WB)  treatments10.
In this study, we investigated the dosimetrical effect of DIBH in prone crawl position on heart, lungs and 
other organs-at-risk (OARs) in both photon and proton plans, for the treatment of WB and LN (including the 
MI chain) as compared to SB. Afterwards, the mortality risk was compared, from radiation dose-related injury 
to heart and induction of lung cancer, to the expected survival benefit of WB + LN radiotherapy in this patient 
population.
Materials and methods
Patient selection. Thirty-one patients with invasive carcinoma of the left breast and pathologically con-
firmed positive lymph node status were included in this study, which was approved by the local ethics board of 
Ghent University Hospital. The age of the patients, at the time of their CT-simulation, ranged between 29 and 
74 years, with a median of 54. All research was performed in accordance with applicable guidelines and regula-
tions and informed consent was obtained from all participants.
Patient set-up. Patients were positioned on the Prone Crawl Breast Couch (Fig. 1 panels a–d) as described 
 previously13. DIBH was monitored using Respisens magnetic sensors (Nomics, Angleur, Belgium) placed on 
the surface of the Breast Couch and lateral thoracic  wall16 (Fig. 1 panels e–f). Patients underwent two com-
puted tomography (CT) scans for radiotherapy planning, first in a short DIBH of around 15 s and later in SB, 
as described  previously17. Patients were instructed to practice the DIBH maneuver in advance at home. CT-
images of 5 mm slice thickness were acquired, starting at below the mandible, and caudally ending below the 
diaphragm. Neither patient positioning nor scan range were altered between DIBH and SB. This was to assure 
that the DICOM coordinate system, indicated by the frame of reference UID of the different scans, remained 
identical.
Target & OAR definition. Target and OARs delineation and margin generation were performed on a Pin-
nacle 9.8 treatment planning system (Philips Healthcare, Fitchburg, Wisconsin, USA) as described  previously13. 
In brief, the whole breast was delineated up to 5 mm from the skin surface as CTV_WBI. CTV_PC included 
axillary level II-IV lymph nodes, delineated using the PROCAB  guidelines18. CTV_MI included the ipsilateral 
MI lymph nodes. Planning target volumes were obtained by performing a 3 mm isotropic expansion of CTV_PC 
and a 1 mm isotropic expansion of CTV_MI, thereby creating PTV_PC and PTV_MI, respectively. PTV_WBI 
was created using a 5 mm margin except towards the skin surface to minimize build-up effects. Photon plan 
optimization structures were created to reduce influence of dose buildup underneath the skin on plan optimiza-
tion and to account for breast swelling. The whole heart was delineated in accordance with guidelines proposed 
by Feng et al.19. The left anterior descending artery (LAD) and the apex were individually delineated. Left and 
right lungs were contoured separately using the automatic segmentation by Hounsfield unit options provided in 
Pinnacle 9.8 with threshold 800–4096. Contralateral breast was delineated up to the skin. Thyroid was delineated 
where visible. The esophagus was delineated starting cranially from the inferior margin of the cricoid and ending 
inferiorly at the gastro-esophageal junction.
Treatment planning. For proton plan optimization, planning CT and structures acquired and contoured 
at Ghent University Hospital were imported in the Paul Scherrer Institut (PSI) treatment planning system in 
Switzerland. The pencil beam scanning (PBS) proton plans were computed using PSIplan, an in-house treatment 
planning  system20. For each proton plan, three oblique anterior fields were used with about 30° of angular spread 
between them (Fig. 1 panel G). Combined target optimization of spot weights was done simultaneously for all 
fields using intensity modulated proton therapy (IMPT)21,22. Detailed information for proton plan optimization 
has been described previously by Speleers et al.13.
For photon plan optimization, a non-coplanar multiple overlying short arc VMAT technique was used, which 
exploits optimal beam directions and reduces low-dose spread to the  OARs13 (Fig. 1 panels H–J). VMAT planning 
tools, developed at Ghent University Hospital as extensions of GRATIS treatment planning platform (Sherouse 
systems, Inc., Chapel Hill, NC, USA), are described  elsewhere19. The final dose calculation was performed using 
the convolution-superposition dose computation engine in Pinnacle 9.8.The objective was a median dose of 
40.05 Gy/GyRBE (prescribed dose) in 15 fractions to the optimization structures related to PTV_WBI, PTV_PC 
and PTV_MI, with 95% of the volumes covered by ≥ 95% of the prescribed dose and no more than 5% receiving 
105% of the prescribed dose. Dose per fraction to the breast, the level II-IV axillary and the ipsilateral MI lymph 
node regions was 2.67 Gy for photons or 2.67 GyRBE/fraction for protons..
Dose statistics. Dose statistics are referred to as Dn (the minimal absolute dose delivered to n % of the vol-
ume) or Vn (the volume percentage receiving ≥ n Gy/GyRBE).  D02 and  D98 were used as surrogates for maximum 
and minimum dose, respectively. Dose is reported for PTV_WBI, PTV_MI and PTV_PC. The dose homogene-
ity index was defined as  (D02–D98)/Dmean. For statistical comparison, two-tailed paired t-tests were performed 
and p ≤ 0.05 considered statistical significance.
Mean dose to heart, LAD, apex, lungs (both lungs together), ipsilateral and contralateral lung, thyroid, esopha-
gus, brachial plexus, spinal cord and contralateral breast are reported.
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Figure 1.  Patient set-up and treatment techniques. (a) Illustration of the prone crawl position for irradiation at the left 
side. (b) Projection of the support surface of the Prone Crawl Breast Couch. (c) Photograph from above and behind of 
a Prone Crawl Breast Couch for irradiation at the left side installed on the couch of a linear accelerator. (1. Prone head 
rest; 2. Arm support blade; 3. Contralateral (untreated) breast support surface; 4. Aperture exposing the ipsilateral 
(treated) breast and its regional lymph nodes; 5. Lower body support surface and 6. Leg support surface). (d,e) 
Photograph from the ipsilateral (d) and contralateral (e) sides of a patient positioned for CT-simulation. The ipsilateral 
breast, lateral thoracic wall and shoulder hardly move with respiration. Therefore, the Respisens sensor system, that 
monitors the breathing cycle and the DIBH maneuver by real-time registration of the distance between 2 sensors, 
is placed at the contralateral thoracic wall. (f) Close-up of the sensors. The upper and lower sensors are taped to the 
lateral thoracic wall of the patient and to an immobile part of the Prone Crawl Breast Couch, respectively. (g) CT-slice 
in the transverse plane through the mid-breast with arrows indicating the 3 beam directions used in proton therapy 
plans. (h–j) Model of an Elekta Synergy linear accelerator with scaled 3D-printed Prone Crawl Breast Couch for left 
side treatment. The arrows give an impression of the arc directions used for photon therapy of the breast and regional 
lymph nodes. (h) Short arc from the ipsilateral side using 0° couch isocenter rotation. (i) Contralateral short arc using 
0°couch isocenter rotation. (j) Para-sagittal arc using 70° couch isocenter rotation.
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The thirty-year mortality risk from radiation-induced cardiac injury and lung cancer for a reference patient, a 
50-year old woman at the time of irradiation, was calculated from mean heart dose and mean dose to both lungs 
according to Taylor et al.7. Risk rates of 0.075%/Gy and 0.3%/Gy were used for patients without or with cardiac 
risk factors, respectively, to calculate cumulative 30-year risk of dying from radiation-induced heart  disease7. 
Risk rates of 0.06%/Gy and 0.88%/Gy were used for non-smoking or smoking patients, respectively, to calculate 
cumulative 30-year risk of dying from radiation-induced lung  cancer7. Cumulative risk of dying from heart dis-
ease and/or lung cancer was calculated as 1 − (1 −  Ph)(1 −  Pl) where  Ph and  Pl are the risks to die from radiation 
induced heart disease or lung cancer, respectively. We then made a risk–benefit classification for different risk 
categories of cardiac events and lung cancer. The line of  regret13 is calculated for the 8% disease-specific absolute 
30-year survival benefit of radiotherapy, based on  literature23. For each patient, mean heart and lung doses are 
plotted onto this graph, showing whether the benefits of radiotherapy can (below the line of regret) or cannot 
(above the line of regret) outweigh the added risks of radiotherapy. The equation of the 8% line of regret (Fig. 4) 
is based on Taylor’s  data7 where 0.92 is derived from the 8% (1–0.08 = 0.92), 0.003 stands for the risk/Gy(RBE) for 
cardiac death for high-risk patients and 0.088 stands for the risk/Gy for lung cancer death for high-risk patients.
Results
Dose to target structures. The dose homogeneity index (HI) was 13.1% for photon DIBH, 12.8% for 
photon SB, 8.80% for proton DIBH and 9.38% for proton SB. HI-differences between photon and proton plans 
are significant for SB (p = 0.002) and DIBH (p = 0.005). Average left breast volume was not significantly different 
at 398  cm3 (range: 45–921) and 393  cm3 (range: 53–902) in SB and DIBH, respectively. Dose objectives were met 
for all targets in all plans.
Figure 2 shows minimum  (D98) and maximum  (D02) dose indices for target volumes in DIBH and SB for both 
photon and proton plans. For photon plans, there were no significant differences in  D98 between DIBH and SB 
for all target structures. For proton plans, there were no significant differences in  D98 between DIBH and SB for 
PTV_WBI. The average  D98 in proton plans was 0.25 GyRBE higher in DIBH than in SB (p = 0.02) for PTV_PC 
and 0.27 GyRBE lower in DIBH than in SB for PTV_MI (p = 0.02).
Regarding the  D02 for PTV_WBI, there were no significant differences between photon DIBH and SB 
(p = 0.11) and between proton DIBH and SB (p = 0.37). For PTV_PC, the average  D02 was 0.36 Gy higher in 
photon DIBH than in photon SB (p = 0.02) and no significant difference was found between proton DIBH and 
proton SB (p = 0.53). For the average maximum doses of PTV_MI, there was no significant difference between 
photon DIBH and SB (p = 0.14), but the average maximum dose was 0.29 GyRBE higher in proton DIBH than 
in proton SB (p = 0.02).
Dose to organs at risk. Dose indices of OARs are summarized in Table 1. The DIBH-technique, compared 
to SB, significantly decreased mean dose to heart in both photon and proton plans. Figure 3 provides an over-
view of the individual mean heart doses for photon (upper panel) and proton (lower panel) irradiation, ranked 
Figure 2.  Dose indices of target structures for photon and proton plans. In the inserted table the parameter 
‘p-value DIBH-SB’ is the p-value of a two-tailed t-test for comparing the dose values between DIBH and SB, 
where p ≤ 0.05 is considered statistical significance.
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according to decreasing mean SB-dose. The mean heart dose reduction in DIBH, compared to SB, for photon 
and proton was on average 2.0 Gy (range: − 1.0 to 3.5) and 0.56 GyRBE (range: 0.1–1.1), respectively.
As seen in Table 1, DIBH also resulted in a significantly lower mean dose for the esophagus for photons, but 
not for protons. On average in photon plans, left lung mean dose decreases about 13% by using DIBH, whereas 
in proton DIBH plans the average mean left lung dose increases by about 21%. No significant difference was 
observed both for proton and photon on the mean dose to the contralateral breast.
As for relevant maximum doses, we saw significantly higher doses in photon than in proton plans for brachial 
plexus and spinal cord. However, for the maximum dose on the esophagus and the mean thyroid dose, proton 
plans show significantly higher doses in both breathing settings.
Analysis of regret. Thirty-year risk estimations of dying from radiation induced heart disease or lung can-
cer (for a 50-year old reference patient) are given in Table 2. Here, two different characteristics have been taken 
into account. The first distinction is based on the presence of cardiac risk factors. The second distinction is based 
on the presence of lung cancer risk factors, in this case long-term smoking behaviour. These rates, multiplied 
with the average mean heart or lung dose in Gy or GyRBE, give an indication of the radiation-induced cardiac 
or lung cancer mortality risk, respectively, for the different groups.
Figure 4 shows a risk–benefit classification of high-risk patients of both cardiac events and lung cancer. For 
none of the patients in this study, the 8% disease-specific survival  benefit23 from radiotherapy would be out-
weighed by radiation-induced cardiac or lung cancer mortality. Data points on the line of regret show where 
the 8% disease-specific survival benefit of radiotherapy is compensated by the survival loss from combined 
radiotherapy-related cardiac and lung cancer mortality.
Discussion
DIBH and prone radiation techniques offer significant dose reductions to heart and lung for breast-only 
 irradiation10,24. In a factorial design study of prone versus supine and DIBH versus SB for WBI, the combination 
of prone positioning and DIBH was shown to achieve lower heart and lung doses than any other  combination10. 
Patients requiring both breast and regional lymph node (locoregional) irradiation receive even higher lung and 
heart doses, but at present technical reasons hamper the combination of DIBH and prone radiotherapy and this 
combination cannot be delivered for routine care. Therefore, we adapted our prone DIBH-technique for use on 
the Prone Crawl Breast Couch and showed the potential of the combination for heart and lung dose reductions 
for irradiation of breast and regional lymph nodes. The relative dose reductions by prone DIBH shown in this 
study, on average 44% mean heart dose reduction by DIBH, are comparable with those previously obtained for 
local radiation by Mulliez (i.e. 45% mean heart dose reduction by DIBH in supine; 41% mean heart dose reduc-
tion in prone)25. Saini reported 48% mean heart dose reduction by DIBH in supine and 9% mean heart dose 
reduction in prone for local  irradiation10. These relative reduction rates establish the role of DIBH in photon 
therapy and support the hypothesis that also for locoregional treatment, the combination of prone positioning 
and DIBH will allow for achieving substantially lower heart and lung doses than the 3 other combinations of 
techniques: supine-SB, supine-DIBH and prone-SB.
In the photon SB plans of this study, the mean heart dose was 4.55 Gy (range: 2.4–6.58). This is about double 
the mean heart dose of 2.54 Gy (range: 1.43–4.31) in the photon DIBH plans. These findings are about the half 
of the 8.7 Gy mean heart dose reported for left-side prone tomotherapy plans by  Kainz26. Taylor et al. reported 
Table 1.  Dose indices of organs-at-risk. Average values (range) for 31 patients. P-values for paired t-test. 
Column 6: p-values for photon DIBH versus photon SB plans. Column 11: p-values for proton DIBH versus 
proton SB plans. Column 12: p-values for DIBH photon versus DIBH proton plans. Column 13: p-values for 
SB photon versus SB proton plans.
Dose (Gy /GyRBE)
Photon Proton Ph/Pr DIBH Ph/Pr SB
DIBH SB p-value DIBH SB p-value p-value p-value
Heart (mean) 2.54 (1.43–4.31) 4.55 (2.40–6.58)  < 0.001 0.78 (0.10–2.11) 1.34 (0.53–2.50)  < 0.001  < 0.001  < 0.001
Heart apex (mean) 4.15 (1.24–14.05) 11.07 (1.51–26.33)  < 0.001 3.44 (0.04–9.56) 4.35 (0.02–12.00) 0.17 0.05  < 0.001
LAD (mean) 6.50 (2.04–17.56) 11.09 (3.02–23.16)  < 0.001 2.19 (0.02–7.56) 2.26 (0.02–14.64) 0.90  < 0.001  < 0.001
Lung left (mean) 4.72 (3.38–6.85) 5.44 (3.93–7.43)  < 0.001 3.70 (2.26–5.57) 3.05 (1.74–4.68)  < 0.001  < 0.001  < 0.001
Lung right (mean) 0.93 (0.26–2.90) 1.04 (0.23–3.36) 0.17 0.14 (0.03–0.46) 0.08 (0.03–0.36) 0.002  < 0.001  < 0.001
Lungs (mean) 2.71 (1.72–4.45) 3.08 (2.04–4.89)  < 0.001 1.78 (1.05–2.80) 1.44 (0.79–2.34)  < 0.001  < 0.001  < 0.001
Esophagus (mean) 2.97 (1.09–6.35) 3.38 (1.16–6.91) 0.02 2.99 (0.24–6.95) 3.27 (0.06–7.43) 0.14 0.90 0.66
Esophagus  (D02) 20.67 (5.17–39.23) 21.23 (2.97–40.35) 0.67 25.45 (3.44–40.98) 25.20 (0.54–40.51) 0.81 0.001 0.02
Thyroid (mean) 5.08 (1.43–16.37) 5.22 (0.78–11.90) 0.77 8.52 (0.77–18.48) 8.49 (0.58–20.26) 0.96  < 0.001  < 0.001
Brachial Plexus  (D02) 43.83 (40.16–49.85) 42.85 (37.36–(47.82) 0.01 41.16 (40.12–42.16) 41.05 (38.32–42.33) 0.40  < 0.001  < 0.001
Spinal cord  (D02) 4.15 (1.06–16.60) 4.38 (0.99–18.89) 0.69 0.19 (0.04–2.67) 0.076152 (0.04–0.60) 0.19  < 0.001  < 0.001
Spinal cord (isotropic 
expansion 5 mm  (D02)
5.50 (1.13–18.10) 5.90 (1.24–25.31) 0.53 0.29 (0.04–3.01) 0.141765 (0.04–0.88) 0.11  < 0.001  < 0.001
Contralateral breast 
(mean) 1.15 (0.25–2.57) 1.18 (0.46–1.88) 0.59 0.11 (0.02–0.25) 0.09 (0.02–0.25) 0.04  < 0.001  < 0.001
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estimations of mean heart doses around 8 Gy from locoregional photon irradiation including the MI-chain 
without breathing  control27. For photons we thus find that non-coplanar VMAT in the prone crawl position 
allows to decrease mean heart dose to lower levels than could be achieved by any other photon technique tested 
by ourselves or known to us from scientific publications. Further decrease of mean heart dose is possible by 
combining prone positioning with DIBH.
Looking at the individual mean heart doses for photon plans in this study, we find lower heart doses in DIBH 
for all patients except one. This is due to the creation of a hotspot in the shoulder, cranially outside the lymph 
node regions. This hotspot derives from the para-sagittal beam direction, as a consequence of trying to spare 
the heart from dose by lateral beam directions, by which the optimizer was struggling during optimization. In 
trying to get rid of the hotspot during optimization, the dose to heart increased by enlarging the beam aperture 
of the lateral beam directions and their dose weights.
Using DIBH in prone crawl position we achieved a mean heart dose of 0.78 GyRBE (range: 0.1–2.11) using 
protons. For proton prone crawl position during SB the mean heart dose was 1.34 GyRBE (0.53–2.5). Taylor et al. 
reported estimations of mean heart doses from locoregional irradiation including the MI-chain using  protons27 
around 2.5 GyRBE. Hence, our results correspond well with previously reported results.
The dose spread difference between the photon and proton modality in this study is clarified in Fig. 5. In the 
intra-thoracic and dorsal shoulder region, ratios of larger dose spread were found for photon (both DIBH and 
SB) than for proton plans, similar to our previous  study13. The main difference in this study is the mutual ratio 
of dose spread in lung between DIBH and SB photon and proton modality, respectively. In the DIBH proton 
setting, we found higher mean lung doses whereby a larger dose spread is seen in low density cavities. This can 
be explained by anatomical differences between SB and DIBH. In SB, the heart occupies a larger part of the left 
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anterior thoracic cavity than in DIBH and displaces lung tissue in dorsal direction out of reach of the proton 
beams. In SB, the heart functions as a “dose absorber” in front of the lung while in DIBH while in DIBH, the “dose 
absorber” is retracted medially and caudally leaving space to lung tissue to move closer to the irradiated breast 
where it can be reached by the proton beams. The lower mean lung dose in DIBH photon plans, compared to SB 
photon plans, can be explained by the use of non-coplanar VMAT beam directions and the gain of unexposed 
lung volume expansion in the posterior and caudal direction by DIBH .
The use of multiple short breath holds of 15–30 s represents the most common mode of implementation of 
DIBH. Clinical experience indicates that multiple short breath-holds are more challenging with the addition 
of regional irradiation. Whereas a local radiotherapy session is typically completed using 3–6 multiple short 
Table 2.  Risk estimations for radiation-induced mortality. Risk estimations for radiation-induced mortality, 
based on Taylor et al.7. Over a 30-year period for a 50-year old (reference) patient, the absolute risk of 
radiation-induced cardiac mortality was estimated 0.075%/Gy and 0.3%/Gy mean heart dose for patients 
without and with cardiac risk factors, respectively. For radiation-induced lung cancer mortality, the risk was 
estimated 0.06%/Gy and 0.88%/Gy mean lung dose (both lungs) for patients who never smoked or continued 
smoking since adolescence, respectively. The rows showing risk cardiac or lung cancer death (1/N) give the 
values of N where 1 out of N reference patients treated would die from radiation-induced cardiac injury 
or lung cancer, respectively, during a 30-year follow-up period. The heart disease*lung cancer mortality is 
the cumulative 30-year risk in (reference) patients who have cardiac risk factors and/or continue smoking. 
Mortality risks can be compared to the disease-specific survival benefit of adjuvant WBI + LNI including MI, 
which we assumed to be ≥ 8% at 30  years23. Legend: The columns ‘p-value DIBH-SB’, ‘p-value Ph/Pr DIBH’ and 
‘p-value Ph/Pr SB’ represent the p-values of a t-test between the results of a comparison between (respectively): 
DIBH and SB, photon and proton for DIBH, and photon and proton for SB.
WBI + LNI + MI
Photon Proton Ph/Pr DIBH Ph/Pr SB
DIBH SB p-value 
DIBH-SB
DIBH SB p-value 
DIBH-SB p-value p-valueMean Range Mean Range Mean Range Mean Range
Heart_mean dose 2.54 (1.43–4.15) 4.55 (2.40–6.58)  < 0.001 0.78 (0.1–2.11) 1.34 (0.53–2.5)  < 0.001  < 0.001  < 0.001




0.19 (0.11–0.31) 0.34 (0.18–0.49) 0.06 (0.01–0.16) 0.10 (0.04–0.19)
Risk cardiac 
death (1/N) 525 (932–321) 293 (556–203) 1712 (1333–632) 994 (2516–533)




0.76 (0.43–1.25) 1.36 (0.72–1.97) 0.23 (0.03–0.63) 0.40 (0.16–0.75)
Risk cardiac 
death (1/N) 131 (233–80) 73 (139–51) 428 (3333–158) 249 (629–133)
Lungs_mean 
dose 2.71 (1.72–4.45) 3.08 (2.04–4.89)  < 0.001 1.78 (1.05–2.80) 1.44 (0.79–2.34)  < 0.001  < 0.001  < 0.001
No smoking
Risk lung cancer 
death (0.06%/
Gy(RBE))
0.16 (0.10–0.27) 0.18 (0.12–0.29) 0.11 (0.06–0.17) 0.09 (0.05–0.14)
Risk lung cancer 
death (1/N) 616 (969–375) 542 (817–341) 936 (1587–595) 1161 (2110–712)
Continuing smoking
Risk lung cancer 
death (0.88%/
Gy(RBE))
2.38 (1.51–3.92) 2.71 (1.80–4.30) 1.57 (0.92–2.46) 1.26 (0.70–2.06)
Risk lung cancer 
death (1/N) 42 (66–26) 37 (56–23) 64 (108–41) 79 (144–49)
Heart disease*lung cancer mortality: 1 − ∏(1 − p) (%)
Low-risk patients 
(no smoking, 
no cardiac risk 
factors) (%)








2.57 (1.62–4.22) 3.04 (1.97–4.78)  < 0.001 1.63 (0.93–2.62) 1.36 (0.73–2.24)  < 0.001  < 0.001  < 0.001
High-risk 
patients (smok-
ing, cardiac risk 
factors) (%)
3.12 (1.94–5.11) 4.03 (2.50–6.19)  < 0.001 1.80 (0.95–3.08) 1.66 (0.85–2.79)  < 0.001  < 0.001  < 0.001
8
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6085  | https://doi.org/10.1038/s41598-021-85401-4
www.nature.com/scientificreports/
breath-holds each of 12–18 s and most patients can be trained to perform these easily, we find that a locore-
gional radiotherapy session requires 10–14 multiple short breath-holds each of 15–30 s. To our experience, 
this represents a substantial physical and mental effort for all but the most able patients . At the University and 
Queen Elizabeth Hospital (Birmingham, UK), a single prolonged breath-hold technique was developed, using 
pre-oxygenation and asymptomatic hypocapnia induced by mechanical  hyperventilation28–32. Volunteers and 
breast cancer patients were able to maintain safely and comfortably single prolonged breath-holds of 5 min and 
more. Another solution could be the use of percussive  ventilation33. An entire locoregional radiotherapy session 
could therefore be delivered in theory in one single prolonged breath-hold. The prolonged breath-hold technique 
is presently being translated for use in the prone crawl position.
Using modern radiation techniques such as IMPT and PBS, proton therapy is able to decrease OAR-dose 
beyond what is possible with photon  techniques13. However, breathing motion may jeopardize the accuracy 
of proton therapy because it may induce uncertainty in proton range and dose prediction. Motion of breast, 
shoulder and sternal regions by breathing is smaller in prone crawl than in supine position and dose prediction 
uncertainty is also expected to be  smaller34. DIBH reduced mean heart, apex and LAD doses on average by 42% 
(0.78–1.34 GyRBE), 21% (3.44–4.35 GyRBE) and 3% (2.19–2.26 GyRBE) respectively, but increased left and right 
lung mean doses by 21% (3.70–3.05 GyRBE) and 75% (0.14–0.08 GyRBE), respectively.The clinical impact is 
highly dependent on patient-individual risk factors, shown in the regret-analysis of Fig. 4. The relative increase 
in dose for both lungs combined was 46%. Epidemiological analyses of the Oxford group suggest that the risk 
of lung cancer induction is linear with the lung mean dose with no  threshold6,7. These investigators fitted the 
epidemiological data to the mean dose of both lungs combined. At present, we lack the parameters to calculate 
risk of lung cancer separately for each lung. The use of couch rotation or novel techniques like proton arc therapy 
and real-time motion monitoring in respiratory-gated PBS proton therapy could mitigate this  issue35. DIBH 
resulted further in small dose increases in esophagus, contralateral (right) breast and spinal cord. The cause of 
opposite dose changes on heart and lung is explained above. Using DIBH in prone locoregional breast proton 
therapy can be beneficial, neutral or detrimental depending on the clinical situation. In patients with cardiac 
but no lung cancer risk factors, overall risk reduction can be expected from DIBH. In patients with lung cancer 
but no cardiac risk factors, SB would be indicated, and end-expiratory breath hold might be worth investigating.
This publication is the first that reports quantitative results of prone DIBH for locoregional irradiation of 
breast cancer. Data on direct comparison of prone DIBH and supine DIBH are inexistant for this patient group. 
For irradiation of the breast only, the 2 existing  publications10,25 show that the lowest mean heart and lung doses 
are achieved for prone DIBH.
During the past decades, gating technology has been developed for photon and proton radiotherapy. Res-
piratory gating requires that the radiation beam starts with minimal delay after the intended breath hold depth 
is reached and is paused immediately after a pre-set length of breath hold or when the breath hold depth is out 
of a pre-set range. Long or unpredictable delays to restart the beam after pausing was a major hurdle to imple-
ment multiple DIBH in the past. This problem is resolved with modern technology and multiple DIBHs can 
be clinically implemented in photon or proton radiotherapy. Errors in DIBH may result in geometrical errors 
of target and OAR shape and position. Geometrical errors generally translate to larger dose errors in proton 
than in photon therapy. Prone DIBH can be expected to be more robust than supine DIBH for photon as well 
as for proton therapy because respiration-related motion of the target volume is smaller in prone than in supine 
 position34, but this needs further investigation.
Figure 4.  Risk–benefit classification of high-risk patients for cardiac events and lung cancer. Risk calculations 
based on cardiac and lung cancer mortality neglect risk-contributions from other radiation-induced 
cancers, such as esophageal, thyroid or contralateral breast cancer. Hence, radiation-related mortality risk is 
underestimated. Taylor’s  data7 are based on a variety of prescription doses, the most common being 25 × 2.0 Gy. 
The prescription dose in this study was 15 × 2.67 Gy. A weakness of these risk calculations is that neither total 
dose nor fractionation could be taken into account.
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Conclusion
We investigated the potential benefits of prone crawl positioning in WB + LN (including MI) RT by evaluating 
the dosimetrical effects of DIBH and SB in photon and proton plans. DIBH significantly decreased doses to heart 
for proton and photon radiotherapy. For photons, the relative reduction establish the role of DIBH in photon 
RT. This supports the hypothesis that also for locoregional treatment, the combination of prone positioning 
and DIBH will allow for achieving substantially lower heart and lung doses than the 3 other combinations of 
techniques: supine-SB, supine-DIBH and prone-SB. For DIBH in proton plans, an increase of lung dose should 
be taken into account. The radiation-related mortality risk could not outweigh the ~ 8% disease-specific survival 
benefit of WB + LN_MI radiotherapy in any of the assessed treatments.
Received: 24 November 2020; Accepted: 23 February 2021
References
 1. Clarke, M. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 
15-year survival: An overview of the randomised trials. Lancet 366, 2087–2106 (2005).
Figure 5.  Transverse dose distribution differences between DIBH and SB photon and proton plans. For photon 
VMAT DIBH and SB (CT scan planes 1–6: a,c) plans, a large dose spread is seen outside the target volumes in 
the dorsal shoulder region and inside the upper  thorax13. For IMPT proton plans, a larger dose spread is clearly 
observed in DIBH where tissues of high density were replaced by tissues of low density (CT scan planes 1–6: 
b,d). Plane 1: lung top. Plane 2: near the cranial edge of the left internal mammary lymph node chain. Plane 3: 
near the cranial edge of the left breast. Plane 4: near the caudal edge of the internal mammary lymph node chain 
at the central part of the left breast. Plane 5: through the caudal quadrants of the left breast. Plane 6: near the 
caudal edge of the left breast. CT scan planes 3–6 show in the SB setting (d) that distal edges of proton pencils 
are located in the heart, blood vessels and pericardial fat. These ‘high’ density tissues protect the lung in SB. In 
the DIBH proton setting (b), high density tissue is replaced by low density lung tissue resulting in increased 
proton range. Proton dose is deposited far outside the deep edge of the target into the left lung tissue in the 
DIBH plan (b) compared to SB plan (d).
10
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6085  | https://doi.org/10.1038/s41598-021-85401-4
www.nature.com/scientificreports/
 2. Darby, S. et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: 
Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 378, 1707–1716 (2011).
 3. Berrington De Gonzalez, A. et al. Second solid cancers after radiation therapy: A systematic review of the epidemiologic studies 
of the radiation dose-response relationship. Int. J. Radiat. Oncol. Biol. Phys. 86, 224–233 (2013).
 4. Grantzau, T., Thomsen, M. S., Væth, M. & Overgaard, J. Risk of second primary lung cancer in women after radiotherapy for breast 
cancer. Radiother. Oncol. 111, 366–373 (2014).
 5. Darby, S. C. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987–998 (2013).
 6. Henson, K. E., McGale, P., Taylor, C. & Darby, S. C. Radiation-related mortality from heart disease and lung cancer more than 20 
years after radiotherapy for breast cancer. Br. J. Cancer 108, 179–182 (2013).
 7. Taylor, C. et al. Estimating the risks of breast cancer radiotherapy: Evidence from modern radiation doses to the lungs and heart 
and from previous randomized trials. J. Clin. Oncol. 35, 1641–1649 (2017).
 8. Mulliez, T. et al. Hypofractionated whole breast irradiation for patients with large breasts: A randomized trial comparing prone 
and supine positions. Radiother. Oncol. 108, 203–208 (2013).
 9. Veldeman, L. et al. The 2-year cosmetic outcome of a randomized trial comparing prone and supine whole-breast irradiation in 
large-breasted women. Int. J. Radiat. Oncol. Biol. Phys. 95 (2016).
 10. Saini, A. S., Das, I. J., Hwang, C. S., Biagioli, M. C. & Lee, W. E. Biological indices evaluation of various treatment techniques for 
left-sided breast treatment. Pract. Radiat. Oncol. 9, e579–e590 (2019).
 11. Deseyne, P. et al. Crawl positioning improves set-up precision and patient comfort in prone whole breast irradiation. Sci. Rep. 10, 
1–13 (2020).
 12. Deseyne, P. et al. Whole breast and regional nodal irradiation in prone versus supine position in left sided breast cancer. Radiat. 
Oncol. 12, 1–12 (2017).
 13. Speleers, B. A. et al. Comparison of supine or prone crawl photon or proton breast and regional lymph node radiation therapy 
including the internal mammary chain. Sci. Rep. 9, 1–9 (2019).
 14. Boute, B. et al. Potential benefits of crawl position for prone radiation therapy in breast cancer. J. Appl. Clin. Med. Phys. 18, 200–205 
(2017).
 15. Mulliez, T. et al. Deep inspiration breath hold in the prone position retracts the heart from the breast and internal mammary lymph 
node region. Radiother. Oncol. 117, 473–476 (2015).
 16. Remouchamps, V. M. et al. The use of magnetic sensors to monitor moderate deep inspiration breath hold during breast irradiation 
with dynamic MLC compensators. Radiother. Oncol. 82, 341–348 (2007).
 17. Mulliez, T. et al. Reproducibility of deep inspiration breath hold for prone left-sided whole breast irradiation. Radiat. Oncol. 10, 
1–6 (2015).
 18. Verhoeven, K. et al. Vessel based delineation guidelines for the elective lymph node regions in breast cancer radiation therapy - 
PROCAB guidelines. Radiother. Oncol. 114, 11–16 (2015).
 19. Feng, M. et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast 
cancer. Int. J. Radiat. Oncol. Biol. Phys. 79, 10–18 (2011).
 20. Pedroni, E. et al. The PSI Gantry 2: A second generation proton scanning gantry. Z. Med. Phys. 14, 25–34 (2004).
 21. Lomax, A. J. et al. Intensity modulated proton therapy: A clinical example. Med. Phys. 28, 317–324 (2001).
 22. Lomax, A. J., Pedroni, E., Rutz, H. & Goitein, G. The clinical potential of intensity modulated proton therapy. Z. Med. Phys. 14, 
147–152 (2004).
 23. McGale, P. et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer 
mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383, 2127–2135 (2014).
 24. Huppert, N., Jozsef, G., DeWyngaert, K. & Formenti, S. C. The role of a prone setup in breast radiation therapy. Front. Oncol. 1, 
1–8 (2011).
 25. Mulliez, T. et al. Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation. Radiother. Oncol. 114, 
79–84 (2015).
 26. Kainz, K. et al. Simultaneous irradiation of the breast and regional lymph nodes in prone position using helical tomotherapy. Br. 
J. Radiol. 85, 899–905 (2012).
 27. Taylor, C. W. et al. Exposure of the heart in breast cancer radiation therapy: A systematic review of heart doses published during 
2003 to 2013. Int. J. Radiat. Oncol. Biol. Phys. 93, 845–853 (2015).
 28. Cooper, H. E., Parkes, M. J. & Clutton-Brock, T. H. CO 2 -dependent components of sinus arrhythmia from the start of breath 
holding in humans. Am. J. Physiol. Heart Circ. Physiol. 285, H841–H848 (2003).
 29. Parkes, M. J. Breath-holding and its breakpoint. Exp. Physiol. 91, 1–15 (2006).
 30. Parkes, M. J. The limits of breath holding. Sci. Am. 306, 63–69 (2012).
 31. Parkes, M. J., Green, S., Stevens, A. M. & Clutton-Brock, T. H. Assessing and ensuring patient safety during breath-holding for 
radiotherapy. Br. J. Radiol. 87, 1–6 (2014).
 32. Parkes, M. J. et al. Safely prolonging single breath-holds to >5 min in patients with cancer; feasibility and applications for radio-
therapy. Br. J. Radiol. 89 (2016).
 33. Sala, I. M., Nair, G. B., Maurer, B. & Guerrero, T. M. High frequency percussive ventilation for respiratory immobilization in 
radiotherapy. Tech. Innov. Patient Support Radiat. Oncol. 9, 8–12 (2019).
 34. Veldeman, L. et al. Alternated prone and supine whole-breast irradiation using IMRT: Setup precision, respiratory movement and 
treatment time. Int. J. Radiat. Oncol. Biol. Phys. 82, 2055–2064 (2012).
 35. Fattori, G. et al. Commissioning and quality assurance of a novel solution for respiratory-gated PBS proton therapy based on 
optical tracking of surface markers. Z. Med. Phys. 30, 1–11 (2020).
Acknowledgements
This work was financed through grant FAF-C/2018/1190 of the Foundation against Cancer. Annick Van Grev-
eling has been funded by a grant of Think-Pink. Liv Veldeman is recipient of post-doctoral clinical mandate of 
Foundation against Cancer. Prototype research is funded by StarTT 241 grant of the Industrial Research Fund, 
Ghent University.
Author contributions
B.S. generated photon plans at Ghent University, Belgium and proton plans at PSI, Switzerland during several 
work visits. F.B., A.B. and B.S. developed prone proton planning techniques, supervised by T.L. and D.W. P.D. and 
L.V. added the internal mammary chain CTV, heart apex and LAD coronary artery to the target and organ-at-risk 
delineations in the patient planning files and performed consensus reviewing of all targets and organs-at-risk. 
A.V.G. performed patient positioning, breath hold training and CT-simulation in prone crawl position. M.S. and 
W.D.N. adapted Prone Crawl Breast Couch types that allowed prone photon and proton radiotherapy of breast 
and regional lymph node irradiation including the internal mammary chain. L.P., T.V. and W.D.G. converted the 
11
Vol.:(0123456789)
Scientific Reports |         (2021) 11:6085  | https://doi.org/10.1038/s41598-021-85401-4
www.nature.com/scientificreports/
data generated in PSI-plan for display and analysis on the GRATIS platform used at Ghent University. W.D.G., 
B.S., M.S., V.V., M.P. and W.D.N. analyzed the data, designed figures and tables and wrote the raw draft of the 
article. All authors were involved in the study design and reviewed the article.
Competing interests 
Ghent University owns the patent application entitled Radiotherapy Board and Couch [WO2015144654A1] filed 
on 25.03.2014 for which Wilfried De Neve, Bruno Speleers and Liv Veldeman are listed as inventors. All other 
authors declare no potential conflict of interest.
Additional information
Correspondence and requests for materials should be addressed to B.S.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2021
